Inference and design of antibody specificity: From experiments to models and back
Exquisite binding specificity is essential for many protein functions but is difficult to engineer. Many biotechnological or biomedical applications require the discrimination of very similar ligands, which poses the challenge of designing protein sequences with highly specific binding profiles. Experimental methods for generating specific binders rely on in vitro selection, which is limited in terms of library size and control over specificity profiles. Additional control was recently demonstrated through high-throughput sequencing and downstream computational analysis. Here we follow such an approach to demonstrate the design of specific antibodies beyond those probed experimentally. We do so in a context where very similar epitopes need to be discriminated, and where these epitopes cannot be experimentally dissociated from other epitopes present in the selection. Our approach involves the identification of different binding modes, each associated with a particular ligand against which the antibodies are either selected or not. Using data from phage display experiments, we show that the model successfully disentangles these modes, even when they are associated with chemically very similar ligands. Additionally, we demonstrate and validate experimentally the computational design of antibodies with customized specificity profiles, either with specific high affinity for a particular target ligand, or with cross-specificity for multiple target ligands. Overall, our results showcase the potential of leveraging a biophysical model learned from selections against multiple ligands to design proteins with tailored specificity, with applications to protein engineering extending beyond the design of antibodies.
Authors
- Jorge Fernández-de-Cossio-Díaz (ORCID: https://orcid.org/0000-0002-4476-805X)
- Andrea Pagnani (ORCID: https://orcid.org/0000-0002-6509-0807)
- Francesca Anselmi (ORCID: https://orcid.org/0000-0002-3163-8598)
- Clément Nizak (ORCID: https://orcid.org/0000-0002-4591-8240)
- Olivier Rivoire (ORCID: https://orcid.org/0000-0002-1820-1324)
- Guido Uguzzoni (ORCID: https://orcid.org/0000-0003-4192-2864)
- Kévin Ricard
Institutions
- Centre National de la Recherche Scientifique (FR)
- Inserm (FR)
- Politecnico di Torino (IT)
- Collège de France (FR)
- Université Paris Cité (FR)
- Université Paris Sciences et Lettres (FR)
- École Normale Supérieure - PSL (FR)
- Sorbonne Université (FR)
- Sorbonne Paris Cité (FR)
- Laboratoire Jean Perrin (FR)
- Istituto Nazionale di Fisica Nucleare, Sezione di Torino (IT)
- Institut de Biologie Paris-Seine (FR)
- Centre Interdisciplinaire de Recherche en Biologie (FR)
- Italian institute for Genomic Medicine (IT)
- Laboratoire de Physique de l'Ecole Normale Supérieure (FR)
- Gulliver (FR)
- University of Turin (IT)
- ESPCI Paris (FR)
Publication Details
- Journal
- PLoS Computational Biology
- Published
- 2024-10-14
- DOI
- https://doi.org/10.1371/journal.pcbi.1012522
- Citations
- 4
- Primary Topic
- Monoclonal and Polyclonal Antibodies Research
- Type
- article
- Field-Weighted Citation Impact
- 1.62
Funders
- European Commission
- Agence Nationale de la Recherche
- Fondation pour la Recherche Médicale
- HORIZON EUROPE Marie Sklodowska-Curie Actions